Gastric cancer is a major malignant disease. The development of new diagnostic techniques and mass screening have led to increased detection rates of patients with early-stage gastric cancer in Japan. However, after curative resection of early gastric cancer, there are various types of recurrences, and residual occult disease and distant micrometastasis precede death. The growth and metastatic potential of cancer cells are closely related to the postoperative outcome, and patients at risk for cancer-related death after surgery have to be closely monitored to prevent tumor recurrence. The biological behavior of cancer cells should be determined in patients with early gastric cancer and with a less favorable prognosis to detect potential early recurrences in the liver. Two types of growth patterns have been found in early gastric cancer: the superficially spreading (Super) type and the penetrating (Pen) type, and the clinicopathological and biological characteristics of each type have been extensively determined. A subtype of the Pen-type gastric cancer, which is progressing expansively with complete destruction of the muscularis mucosae (Pen A type) has a less favorable prognosis due to early recurrences in the liver. These clinical cancer types are closely related to chromosomal instability in DNA aneuploidy and p53 overexpression, and vascular endothelial growth factor activation induced tumor angiogenesis, vascular invasion and hematogenous metastasis. Thus, patients with Pen-A-type cancer showing expansive tumor growth had a poorer postoperative outcome and a hematogenous-related recurrence of the cancer. Antiangiogenic approaches in a postoperative setting may prove to be effective in preventing tumor recurrence and improving the prognosis for these patients.

Keywords:
Early gastric cancer, Growth pattern, Prognosis, DNA ploidy, p53 overexpression, Tumor angiogenesis
1.
Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995;333:32–41.
2.
Moreaux J, Bougaran J: Early gastric cancer. A 25-year surgical experience. Ann Surg 1993;217:347–355.
3.
Maehara Y, Oshiro T, Oiwa H, Oda S, Baba H, Akazawa K, et al: Gastric cancer in patients over 70 years of age. Br J Surg 1995;82:102–105.
4.
Maehara Y, Okuyama T, Oshiro T, Baba H, Anai H, Akazawa K, et al: Early carcinoma of the stomach. Surg Gynecol Obstet 1993;177:593–597.
5.
Yoshimori M: The natural history of early gastric cancer. Jpn J Clin Oncol 1989;19:89–93.
6.
Murakami T: Early cancer of the stomach. World J Surg 1979;3:685–692.
7.
Maehara Y, Moriguchi S, Orita H, Kakeji Y, Haraguchi M, Korenaga D, et al. Lower survival rate for patients with gastric carcinoma of Borrmann type IV following gastric resection. Surg Gynecol Obstet 1992;175:13–16.
8.
Kaneko E, Nakamura T, Umeda N, Fujino M, Niwa H: Outcome of gastric carcinoma detected by gastric mass survey in Japan. Gut 1977;18:626–630.
9.
Noguchi Y, Imada T, Matsumoto A, Coit DG, Brennan MF: Radical surgery for gastric cancer. A review of the Japanese experience. Cancer 1989;64:2053–2062.
10.
Maehara Y, Kakeji Y, Oda S, Takahashi I, Akazawa K, Sugimachi K: Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer 2000;83:986–991.
11.
Abe S, Lightdale CJ, Brennan MF: The Japanese experience with endoscopic ultrasonography in the staging of gastric cancer. Gastrointest Endosc 1993;39:586–591.
12.
Korenaga D, Okamura T, Baba H, Saito A, Sugimachi K: Results of resection of gastric cancer extending to adjacent organs. Br J Surg 1988;75:12–15.
13.
Maehara Y, Okuyama T, Moriguchi S, Orita H, Kusumoto H, Korenaga D, et al: Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time. Cancer 1992;70:392–395.
14.
Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y, et al: Recurrences and related characteristics of gastric cancer. Br J Cancer 1996;74:975–979.
15.
Kodama Y, Sugimachi K, Soejima K, Matsusaka T, Inokuchi K: Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981;5:241–248.
16.
Sue-Ling HM, Johnston D, Martin IG, Dixon MF, Lansdown MR, McMahon MJ, et al: Gastric cancer: A curable disease in Britain. Gut 1993;307:591–596.
17.
Jentschura D, Heubner C, Manegold BC, Rumstadt B, Winkler M, Trede M: Surgery for early gastric cancer: A European one-center experience. World J Surg 1997;21:845–849.
18.
Moriguchi S, Maehara Y, Korenaga D, Kakeji Y, Sugimachi K, Nose Y: The relationship between prognostic significance of pathological type and the degree of gastric wall invasion in gastric cancer. Cancer J 1992;5:220–223.
19.
Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K: Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 2000;87:353–357.
20.
Kodama Y, Inokuchi K, Soejima K, Matsusaka T, Okamura T: Growth patterns and prognosis in early gastric carcinoma. Cancer 1983;51:320–326.
21.
Folli S, Dente M, Dell’Amore D, Gaudio M, Nanni O, Saragoni L, et al: Early gastric cancer: Prognostic factors in 223 patients. Br J Surg 1995;82:952–956.
22.
Ming SC: Gastric carcinoma: A pathobiological classification. Cancer 1977;39:2475–2485.
23.
Noda S, Soejima K, Inokuchi K: Clinicopathological analysis of the intestinal type and diffuse type of gastric carcinoma. Jpn J Surg 1980;10:227–283.
24.
Laurén P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31–49.
25.
Matsusaka T, Kodama Y, Soejima K, Miyazaki M, Yoshimura K, Sugimachi K, et al: Recurrence in early gastric cancer: A pathologic evaluation. Cancer 1980;46:168–172.
26.
Ohno S, Mori M, Tsutsui S, Matsuura H, Kuwano H, Soejima K, et al: Growth patterns and prognosis of submucosal carcinoma of the esophagus. Cancer 1991;68:335–340.
27.
Inokuchi K, Kodama Y, Sasaki O, Kamegawa T, Okamura T: Differentiation of growth patterns of early gastric carcinoma determined by cytophotometric DNA analysis. Cancer 1983;51:1138–1141.
28.
Naora H: Microspectrophotometry of cell nucleus stained by Feulgen reaction: I. Microspectrophotometric apparatus without Schwarzschild-Villiger effect. Exp Cell Res 1955;8:259–278.
29.
Korenaga D, Mori M, Okamura T, Sugimachi K, Enjoji M: DNA ploidy in clinical malignant gastric lesions less than 5 mm in diameter. Cancer 1986;58:2542–2545.
30.
Korenaga D, Okamura T, Saito A, Baba H, Sugimachi K: DNA ploidy is closely linked to tumour invasion, lymph node metastasis, and prognosis in clinical gastric cancer. Cancer 1988;62:309–313.
31.
Korenaga D, Haraguchi M, Okamura T, Baba H, Saito A, Sugimachi K: DNA ploidy and tumor invasion in human gastric cancer. Arch Surg 1989;124:314–318.
32.
Haraguchi M, Watanabe A, Moriguchi S, Korenaga D, Maehara Y, Okamura T, et al: DNA ploidy is a major prognostic factor in advanced gastric carcinoma – univariate and multivariate analysis. Surgery 1991;110:814–819.
33.
Korenaga D, Saito A, Baba H, Watanabe A, Okamura T, Maehara Y, et al: Cytophotometrically determined DNA content, mitotic activity, and lymph node metastasis in clinical gastric cancer. Surgery 1990;107:262–267.
34.
D’Agnano I, D’Angelo C, Savarese A, Bottari L, Santoro E, Giannarelli D, et al: DNA ploidy, proliferative index, and epidermal growth factor receptor: Expression and prognosis in patients with gastric cancers. Lab Invest 1995;72:432–438.
35.
Okusa Y, Shinomiya N, Ichikura T, Mochizuki H: Correlation between telomerase activity and DNA ploidy in gastric cancer. Oncology 1998;55:258–264.
36.
Haraguchi M, Korenaga D, Kakeji Y, Orita H, Maehara Y, Sugimachi K: DNA ploidy is associated with growth potential in gastric carcinoma. Cancer 1991;68:2608–2611.
37.
Oiwa H, Maehara Y, Ohno S, Sakaguchi Y, Ichiyoshi Y, Sugimachi K: Growth pattern and p53 overexpression in patients with early gastric cancer. Cancer 1995;75:1454–1459.
38.
Banks L, Matlashewski G, Crawford L: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529–534.
39.
Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, et al: p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomark Prevent 1995;4:223–231.
40.
Harris CC, Hollstein M: Clinical implications of the p53 tumour-suppressor gene. N Engl J Med 1993;329:1318–1327.
41.
Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer. A review. Int J Cancer 1994;57:1–9.
42.
Chang F, Syrjänen S, Syrjänen K: Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009–1022.
43.
Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, et al: Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst 1991;83:938–943.
44.
Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S: p53 mutation in gastric cancer: A genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 1993;54:759–764.
45.
Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991;351:453–456.
46.
Carson DA, Lois A: Cancer progression and p53. Lancet 1995;346:1009–1011.
47.
Oren M: The p53 cellular tumor antigen: Gene structure, expression and protein properties. Biochim Biophys Acta 1985;823:67–78.
48.
Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531–539.
49.
Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595–1602.
50.
Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y, et al: Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer 1993;67:589–593.
51.
Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F: p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859–862.
52.
Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogaston SA, et al: The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994;69:943–946.
53.
Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y, et al: Prognostic value of p53 protein expression for patients with gastric cancer – A multivariate analysis. Br J Cancer 1999;79:1255–1261.
54.
Maehara Y, Orita H, Okuyama T, Moriguchi S, Tsujitani S, Korenaga D, et al: Predictors of lymph node metastasis in early gastric cancer. Br J Surg 1992;79:245–247.
55.
Schneider BG, Hilsenbeck SG, Hensel CH, Pekkel V, Shelton CH, Rodriguez-Martinez HA, et al: p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos. Virchows Arch 1994;424:187–193.
56.
Motojima K, Furui J, Kohara N, Ito T, Kanematsu T: Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 1994;116:890–895.
57.
Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G: The relationship of p53 expression to the prognosis of 418 patients with gastric cancer. Cancer 1995;76:720–726.
58.
McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992;66:735–738.
59.
Wynford-Thomas D: p53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 1992;166:329–330.
60.
Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, et al: Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57–64.
61.
Kang SM, Maeda K, Onoda N, Chung YS, Nakata B, Nishiguchi Y, et al: Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 1997;74:502–507.
62.
Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Yamashita J, Matsuda M, et al: Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer 1998;82:1238–1243.
63.
Takahashi Y, Bucana CD, Cleary KR, Ellis LM: p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998;79:34–38.
64.
Furihata M, Ohtsuki Y, Sonobe H, Shuin T, Yamamoto A, Terao N, et al: Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvic and ureter. Br J Cancer 1998;77:783–788.
65.
Weinert TA, Hartwell LH: The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 1988;241:317–322.
66.
O’Connor PM, Ferris DK, White GA, Pines J, Hunter T, Longo DL, et al: Relationships between cdc2 kinase. DNA, crosslinking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ 1992;3:43–52.
67.
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587–597.
68.
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491–7495.
69.
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923–935.
70.
Carder P, Wyllie AH, Purdie CA, Morris RG, White S, Piris J, et al: Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 1993;8:1397–1401.
71.
Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, et al: A p53-dependent mouse spindle checkpoint. Science 1995;267:1353–1356.
72.
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88–91.
73.
Craanen ME, Blok P, Top B, Boerrigter L, Dekker W, Offerhaus GJ, et al: Absence of ras gene mutations in early gastric carcinomas. Gut 1995;37:758–762.
74.
Blok P, Craanen ME, Dekker W, Tytgat GNJ: Loss of E-cadherin expression in early gastric cancer. Histopathology 1999;34:410–415.
75.
Blok P, Craanen ME, Dekker W, Offerhaus GJ, Tytgat GN: No evidence for c-erbB-2 overexpression in gastric carcinogenesis. Histopathology 1998;32:335–339.
76.
David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, et al: c-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol 1992;5:384–390.
77.
Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.
78.
Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
79.
Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, et al: Tumor angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995;72:319–323.
80.
Gospodarowicz D, Abraham JA, Schilling J: Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc Natl Acad Sci USA 1989;86:7311–7315.
81.
Ferrara N, Houck KA, Jakemen LB, Winer J, Leung DW: The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211–218.
82.
Ferrara N, Houch K, Jakeman L, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18–32.
83.
Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996;77:858–863.
84.
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.
85.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875–1887.
86.
Maeda K, Chung YS, Takatsuka S, Ogawa Y, Sawada T, Yamashita Y, et al: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 1995;13:477–481.
87.
Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, et al: Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603–1612.
88.
Tomisaki S, Ohno S, Ichiyoshi Y, Kuwano H, Maehara Y, Sugimachi K: Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 1996;77:1722–1728.
89.
Skinner SA, Tutton PJM, O’Brien PE: Microvascular architecture of experimental colon tumors in the rat. Cancer Res 1990;50:2411–2417.
90.
Jain RK: Determinants of blood flow: A review. Cancer Res 1988;48:2641–2658.
91.
Fukumura D, Salehi HA, Witwer B, Tuma RF, Melder RJ, Jain RK: Tumor necrosis factor α-induced leukocyte adhesion in normal and tumor vessels: Effect of tumour type, transplantation site, and host strain. Cancer Res 1995;55:4824–4829.
92.
Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029–1039.
93.
Roy S, Sarkar C: Ultrastructural study of micro-blood vessels in human brain tumors and peritumoural tissue. J Neurooncol 1989;7:283–294.
94.
Caruso RA, Cicciarello R, d’Aquino A, Inferrera C: Ultrastructural study of the vascular response in small early gastric cancer. Histol Histopathol 1996;11:17–25.
95.
Nagy JA, Brown LF, Senger DR, Lanir N, Van d WL, Dvorak AM, et al: Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305–326.
96.
Roberts WG, Palade GE: Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997;57:765–772.
97.
Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer 1997;80:1529–1537.
98.
Waleh NS, Brody MD, Knapp MA, Mendonca HL, Lord EM, Koch CJ, et al: Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Res 1995;55:6222–6226.
99.
Tomoda M, Maehara Y, Kakeji Y, Ohno S, Ichiyoshi Y, Sugimachi K: Intratumoral neovascularization and growth pattern in early gastric carcinoma. Cancer 1999;85:2340–2346.
100.
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.
101.
Shweiki D, Neeman M, Itin A, Keshet E: Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumour angiogenesis. Proc Natl Acad Sci USA 1995;92:768–772.
102.
Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–845.
103.
Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845–848.
104.
Dewhirst MW: Angiogenesis and blood flow in solid tumors; in Teicher BA (ed): Drug Resistance in Oncology. New York, Dekker, 1993, pp 3–24.
105.
Vaupel PW: Oxygenation of solid tumors; in Teicher BA (ed): Drug Resistance in Oncology. New York, Dekker, 1993, pp 53–85.
106.
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604–4613.
107.
Kieser A, Weich HA, Brandner G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963–969.
108.
Mukhopadhyay D, Tsiokas L, Sukhatme VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161–6165.
109.
Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O’Byrne K, Scott PA, et al: Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998;4:3017–3024.
110.
Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana C, et al: Adenovirus-mediated wild-type p53 gene transfer downregulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998;58:2288–2292.
111.
Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N: Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma. Oncology 1999;57:164–172.
112.
Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, et al: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000;128:408–415.
113.
Kakeji Y, Maehara Y, Shibahara K, Hasuda S, Tokunaga E, Oki E, et al: Clinical significance of micrometastasis in bone marrow of patients with gastric cancer and its relation to angiogenesis. Gastric Cancer 1999;2:46–51.
114.
Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749–1756.
115.
Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G: Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685–689.
116.
Cote RJ, Beattie EJ, Chaiwun B, Shi SR, Harvey J, Chen SC, et al: Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415–425.
117.
Jauch KW, Heiss MM, Gruetzner U, Funke I, Pantel K, Babic R, et al: Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 1996;14:1810–1817.
118.
Schlimok G, Funke I, Bock B, Schweiberer B, Witte J, Riethmuller G: Epithelial tumour cells in bone marrow of patients with colorectal cancer: Immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol 1990;8:831–837.
119.
Maehara Y, Yamamoto M, Oda S, Baba H, Kusumoto T, Ohno S, et al: Cytokeratin-positive cells in bone marrow for identifying distant micrometastasis of gastric cancer. Br J Cancer 1996;73:83–87.
120.
Maehara Y, Hasuda S, Abe T, Oki E, Kakeji Y, Ohno S, et al: Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer. Clin Cancer Res 1998;4:2129–2134.
121.
Schlimok G, Funke I, Pantel K, Strobel F, Kindemann F, Witte J, et al: Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance. Eur J Cancer 1991;27:1461–1465.
122.
Okamura T, Korenaga D, Baba H, Saito A, Sugimachi K: Postoperative adjuvant chemotherapy inhibits early recurrence of early gastric carcinoma. Cancer Chemother Pharmacol 1989;23:319–322.
123.
Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, et al: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999;5:2185–2191.
124.
Au JL, Sadee W: Activation of Ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and γ-butyrolactone. Cancer Res 1980;40:2814–2819.
125.
Kakeji Y, Teicher BA: Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39–48.
126.
Teicher BA, Emi Y, Kakeji Y, Northey D: TNP-470/minocycline/cytotoxic therapy: A system approach to cancer therapy. Eur J Cancer 1996;32A:2461–2466.
127.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841–844.
128.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315–328.
129.
O’Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689–692.
130.
Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, et al: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293–298.
131.
Rasmussen HS, McCann PP: Matrix metalloproteinase inhibiton as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69–75.
132.
Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99–106.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.